Recent Developments in Myelodysplastic Syndromes最新文献

Diagnosis and Classification of Myelodysplastic Syndrome 骨髓增生异常综合征的诊断和分类

Recent Developments in Myelodysplastic Syndromes Pub Date : 2019-01-30 DOI: 10.5772/INTECHOPEN.82532

Gamal Abdul Hamid, Abdul Wahab Al-Nehmi, S. Shukry

{"title":"Diagnosis and Classification of Myelodysplastic Syndrome","authors":"Gamal Abdul Hamid, Abdul Wahab Al-Nehmi, S. Shukry","doi":"10.5772/INTECHOPEN.82532","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.82532","url":null,"abstract":"Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disorder characterized by morphological dysplastic changes in one or more of the major hematopoietic cell lines. MDS can present with varying degrees of single or multiple cytopenias including neutropenia, anemia and thrombocytopenia. Presentation of MDS can range from asymptomatic to life threatening. MDS diagnosis and classification present important challenges, particularly in the distinction from benign conditions. French-American-British (FAB) classification proposed a classification based on easily obtainable laboratory information and was recommended in early and as modified by guidelines of new classification of World Health Organization (WHO). The strategy of diagnostic laboratory in MDS depends on morphological changes and is based on existence of dysplastic changes in the peripheral blood and bone marrow including peripheral blood smear, bone marrow aspirate smear and bone marrow trephine biopsy. The correct morphological interpretation and the use of cytogenetics, immunophenotyping, immunohistochemistry and molecular analysis will give valuable information on diagnosis and prognosis.","PeriodicalId":405900,"journal":{"name":"Recent Developments in Myelodysplastic Syndromes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124742900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Introductory Chapter: Progress in Myelodysplastic Syndrome Area 导论:骨髓增生异常综合征领域的研究进展

Recent Developments in Myelodysplastic Syndromes Pub Date : 2019-01-29 DOI: 10.5772/INTECHOPEN.84594

O. Fuchs

引用次数: 0

Immune Dysregulation in MDS: The Role of Cytokines and Immune Cells MDS的免疫失调:细胞因子和免疫细胞的作用

Recent Developments in Myelodysplastic Syndromes Pub Date : 2019-01-28 DOI: 10.5772/INTECHOPEN.82101

Selma Z D'silva, S. Rajadhyaksha, Meenakshi Singh

引用次数: 4

Myelodysplastic Syndromes: An Update on Pathophysiology and Management 骨髓增生异常综合征:病理生理学和治疗的最新进展

Recent Developments in Myelodysplastic Syndromes Pub Date : 2018-11-27 DOI: 10.5772/INTECHOPEN.82166

W. Chai-Ho, G. Schiller

引用次数: 1

Noncoding RNAs in Myelodysplastic Syndromes 骨髓增生异常综合征中的非编码rna

Recent Developments in Myelodysplastic Syndromes Pub Date : 2018-11-05 DOI: 10.5772/INTECHOPEN.79767

A. Hruštincová, K. Szikszai, Z. Krejcík, Nikoleta Loudová, M. Merkerová

引用次数: 2

Myelodysplastic Syndrome and Autoimmune Disorders: Causal Relationship or Coincidence? 骨髓增生异常综合征与自身免疫性疾病:因果关系还是巧合?

Recent Developments in Myelodysplastic Syndromes Pub Date : 2018-11-05 DOI: 10.5772/INTECHOPEN.80710

K. Newman, M. Akhtari, S. Heidarian

{"title":"Myelodysplastic Syndrome and Autoimmune Disorders: Causal Relationship or Coincidence?","authors":"K. Newman, M. Akhtari, S. Heidarian","doi":"10.5772/INTECHOPEN.80710","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.80710","url":null,"abstract":"Myelodysplastic syndromes are heterogeneous group of clonal hematologic malignancies characterized by peripheral blood cytopenias secondary to the ineffective hematopoiesis. ADs are frequently reported in MDS, the incidence ranging from 10 to 30%, and particularly ADs are more frequently seen at CMML. ADs may prone patient to MDS, especially when immune suppressors such as azathioprine are used for the underlying AD. Both innate and adaptive immune systems, and different cytokines including interleukins, TNF- α , and C-X-C motif chemokine 10 (CXCL10) contribute in immune dysregulation of MDS. Vasculitis, seronegative rheumatoid arthritis, SLE, Behçet ’ s disease, RP, and AIHA are just some of the ADs occurring concomitantly with MDS. Although hematopoietic growth factors are recommended by the American Society of Clinical Oncology (ASCO), it has been recognized from several case reports that treatment of the underlying MDS may resolve the associated autoimmune disorders. The heterogeneity and complexity of pathology, clinical manifestations, response to therapy, and prognosis of MDS and its immune dysregulation make the prognosis of MDS with autoimmune diseases a matter of debate. Better understanding of the immune dysregulation of MDS in the molecular level may help to design prospective, double blind clinical trials to find the best treatment options for autoimmune disorders associated with MDS. vasculitis, chronic inflammatory demyelinating polyneuropathy (CIDP), neutrophilic dermatosis, Henoch-Schonlein purpura, relapsing polychondritis (RP), granulomatosis with polyangiitis (GPA), giant cell arteritis (GCA), polyarteritis nodosa (PAN)","PeriodicalId":405900,"journal":{"name":"Recent Developments in Myelodysplastic Syndromes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132244713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1